Signatur Biosciences raises $7m in seed funding to advance decentralised breast cancer diagnostics.
The seed round was led by The Discovery Lab of IBA to support product validation and laboratory expansion.
≈ £5.2M at $1 = £0.7452 on 22 May 2025
Precision diagnostics startup developing decentralised molecular tests for cancer care.
Signatur Biosciences has secured $7m in a seed round led by The Discovery Lab of IBA, with participation from Noshaq and other strategic backers. The capital brings the company's total funding to $9.9m.
The funds will be directed towards finalising and validating its flagship breast cancer prognostic test, unlocking public grants, establishing a new laboratory in Belgium, and expanding the team for ongoing research and commercialisation.
The company develops decentralised diagnostic solutions designed to run on standard hospital equipment, aiming to reduce costs and delivery times for clinical testing.
From the founder
"Advanced diagnostics shouldn’t be gated by geography – the centre of gravity for precision diagnostics needs to shift. We founded Signatur to change the way molecular diagnostics are delivered. This funding brings us closer to ensuring that patients can benefit from precision testing no matter where they are. By turning complex lab processes into simple kits, we’re giving control back to hospitals across Europe and beyond. This funding is a step toward a more resilient and self-sufficient diagnostic ecosystem"
Celestin de Wergifosse
CEO at Signatur Biosciences
Use of funds
- 01Continue product development
- 02Fund research and development
- 03Expand into international markets
- 04Grow the team
Investors
Categories
About the company
Signatur Biosciences
Signatur Biosciences develops decentralised molecular diagnostic tests for local hospital use.